title: Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?
authors.affiliation: Mario Uccello, Michele Moschetta, and Hendrik-Tobias Arkenau, Sarah Cannon Research Institute UK, London, United Kingdom.
authors.forename: Mario
authors.initials: M
authors.lastname: Uccello
authors.affiliation: Mario Uccello, Michele Moschetta, and Hendrik-Tobias Arkenau, Sarah Cannon Research Institute UK, London, United Kingdom.
authors.forename: Michele
authors.initials: M
authors.lastname: Moschetta
authors.affiliation: Mario Uccello, Michele Moschetta, and Hendrik-Tobias Arkenau, Sarah Cannon Research Institute UK, London, United Kingdom.
authors.forename: Hendrik-Tobias
authors.initials: HT
authors.lastname: Arkenau
mesh_terms: D003841:Deoxycytidine / Q000031:analogs & derivatives; D005472:Fluorouracil; D006801:Humans; D002955:Leucovorin; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms; D000093542:Gemcitabine
chemical_list: D000077150:Oxaliplatin; D003841:Deoxycytidine; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine